Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Should l Buy ?
Source: Newsfilter
Company Rebranding and Relocation: Insight Molecular Diagnostics Inc. (iMDx), formerly Oncocyte Corporation, has rebranded to better reflect its focus on precision biomarker-based testing for transplant and oncology care, and is relocating its headquarters from Irvine, California to Nashville, Tennessee.
Product Development and Exhibition Plans: iMDx is launching new product names under the GraftAssure brand and will showcase its GraftAssureIQ™ research-use-only kits at the European Society of Organ Transplantation conference in London, aiming to enhance collaboration in transplant medicine research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
